Patterns of antibiotic use, pathogens, and prediction of mortality in hospitalized neonates and young infants with sepsis: A global neonatal sepsis observational cohort study (NeoOBS)
Fig 1
(A) Initial empiric baseline therapy overall and by site. (B) First change of initial regimen, by baseline regimen. (C) Cumulative incidence of stopping all IV antibiotics (death on IV antibiotics as competing risk). Group 1 = First-line WHO-recommended penicillin-based regimen (e.g., ampicillin and gentamicin) (Access). Group 2 = third-generation cephalosporin (e.g., cefotaxime/ceftriaxone)-based WHO regimens (“Low” Watch). Group 3 = regimens with partial anti-ESBL or pseudomonal activity (e.g., piperacillin-tazobactam/ceftazidime/fluoroquinolone-based) (“Medium” Watch). Group 4 = Carbapenems (“High” Watch). Group 5 = Reserve antibiotics targeting carbapenem-resistant organisms (e.g., colistin). ESBL, extended-spectrum beta-lactamase; IV, intravenous.
doi: https://doi.org/10.1371/journal.pmed.1004179.g001